Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Predisposing factors for nevirapine toxicity among AIDS patients with low baseline CD4 count
Authors: Somsit Tansuphaswadikul
Saw Eindani Aung
Benjaluck Phonrat
Jaranit Kaewkungwal
Punnee Pitisuttithum
Wirach Maek-a-nantawat
Bamrasnaradura Infectious Disease Institute
Mahidol University
Keywords: Immunology and Microbiology;Medicine
Issue Date: 1-Jun-2007
Citation: Asian Pacific Journal of Allergy and Immunology. Vol.25, No.2-3 (2007), 147-154
Abstract: The objective of the study was to determine the predisposing factors and incidence of toxicity among AIDS patients treated with a nevirapine (NVP)-based regimen in clinical practice. A retrospective cohort study of representative samples of AIDS patients treated with a NVP-based regimen was performed. A total of 206 adult HIV/AIDS cases with median age (IQR) 33 years (range, 29-38 years), 51% male, treated between January 2004-December 2005, were included. Most (92.2%) of the patients were naïve to antiretroviral drug. The incidence of NVP toxicity was 1.09/100 person-months. The median onset time was 4 weeks post NVP initiation (2.57 weeks for skin toxicity and 12.43 weeks for hepatic toxicity). History of drug allergy and NVP toxicity were significantly associated (p = 0.006), as were sulfamethoxazole allergy and toxicity (p = 0.015). Regarding concomitant medication, concurrent anti-tuberculosis drugs significantly increased the risk of NVP associated liver toxicity (p = 0.001). Therefore, it is important to monitor adverse events from NVP, including liver function tests among HIV/AIDS patients with history of drug allergy, especially against sulfamethoxazole, and those concurrently treated with anti-tuberculosis drugs.
ISSN: 0125877X
Appears in Collections:Scopus 2006-2010

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.